Latest News & Features
Americas
The ability of third parties to participate in patent challenges has led to new dynamics, including the possibility of parties profiting from movements in stock price and the prospect of patent oppositions by not-for-profit proxies, as Marc Cavan and Phillip Kurs of law firm Ropes & Gray describe. 14 May 2015
Americas
LSIPR takes a look at what the Practical Law Life Sciences Forum, due to take place on June 25, has to offer. 12 May 2015
Americas
Many NPEs have been using their well-stocked war chests to build massive patent portfolios in the medical technology sector, so right owners need to be prepared for a fresh wave of litigation. Jay Nuttall of Steptoe & Johnson offers some tips. 7 May 2015
Biotechnology
For companies that are considering conducting patent litigation around the world, the EPO is a very useful forum for testing their strategy or opposition tactics at a relatively low cost. Hazel Ford and Leythem Wall of Finnegan, Henderson, Farabow, Garrett & Dunner describe the numerous advantages of the procedures available. 30 April 2015
Europe
In the second instalment of a regular column on the unitary patent and Unified Patent Court by law firm Taylor Wessing, Paul England and Simon Cohen discuss how watching the new system will also mean monitoring the old one. 23 April 2015
Americas
A product of decomposing leaf litter, exDNA could be a powerful tool for interacting with biological systems. If so, the IP associated with its applications may be an active area in the coming years, says non-practising barrister Charles Brabin. 16 April 2015
Genetics
The new CRISPR-Cas9 gene-editing system is set to revolutionise the treatment of genetic diseases, but there’s a fight to secure rights to the platform. LSIPR takes a look at the major players in this exciting technology area, and what patent disputes may arise as it develops. 9 April 2015
Americas
There are important differences between the EPO and the USPTO in the assessment of patentable subject matter in life sciences. Depending on the technology involved, patentees may elect national or regional applications as a useful alternative to PCT filings, as Joachim Wachenfeld and Oswin Ridderbusch explain. 2 April 2015
Biotechnology
Some of the parties involved in the landmark patent case Biogen v Medeva met in London in February to discuss the dispute in front of an invited audience. Here is an overview of their memories and the lessons they learned. 25 March 2015
Big Pharma
Orphan medicinal products in Europe benefit from a range of incentives, but the greatest of these is the promise of receiving a ten-year period of true market exclusivity, says Trevor Cook of Wilmer Cutler Pickering Hale and Dorr. 20 March 2015